Work-life harmony, failing earlier, and the human side of biotech.

BLPN Series | Episode 2 of 4

In the second episode of the BLPN Series, Deborah, Karim, and Vassili sit down with Chandima “Chandi”  Bandaranayaka, CEO of Precision Quantomics, for a follow-up after the Moneyball program at BIO and a real look at what it means to build when life is also happening. Chandi shares the story of rushing home from BIO as his two-year-old landed in the ICU, and how that moment sharpened the “why” behind his company’s mission: helping drug developers see earlier, with better biological signal, how therapies may behave across human populations, including pediatrics.

From there, the conversation moves into the messy, necessary idea of “failing earlier” in pharma. Chandi explains how quantitative proteomics can add a critical layer of data to PBPK modeling and modern AI workflows, reducing late-stage surprises, saving capital, and protecting patients. The group also gets practical in classic BLPN fashion: what’s real today (assay kits in use with pharma), what’s still being built (their Translational Proteomics Atlas), and who the ideal partners are right now, including organ-on-a-chip and microphysiological systems teams. And yes, Deborah leans fully into her role as biotech’s “Hitch,” asking the best question founders rarely get asked: if we were setting your company up on a first date, who are you trying to meet?

This episode is about purpose under pressure, the courage to learn the truth sooner, and the BLPN mindset in motion: find someone who can help, make the connection, and keep building.